At Functional Medicine University (FMU), this philosophy is central to how we train practitioners helping them move from managing disease to restoring function
( a - d ) Observed data for participants in the full analysis set treated with semaglutide 2.4 mg (a, c) or placebo (b, d) during the in-trial period
In Phase 2 trials, the 12 mg dose produced an average of 24.2% body weight reduction over 48 weeks
19-24 Liraglutide has been studied as monotherapy and in combination with metformin, the SU glimepiride, the TZD rosiglitazone, or insulin glargine, and in combination with glimepiride and rosiglitazone, or metformin and an SU
The GIP portion strengthens these effects and may improve fat metabolism
Around 50,000 of BCBS' 3 million members were reportedly taking a GLP-1 as of Jan